文献速递核素与放射性配体治疗肿瘤 PET/CT

188Re-SSS Lipiodol经动脉放疗栓塞治疗肝细胞癌的I期Lip-Re 1初步结果:生物分布与剂量学评估

Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-02-04

本研究报道了I期Lip-Re 1试验中前6例肝细胞癌患者经肝动脉注射188Re-SSS Lipiodol后的生物分布与剂量学初步结果。平面闪烁显像和SPECT显示摄取仅见于肝脏(肿瘤和健康肝)和肺部,且随时间稳定。平均注射活度为1645 ± 361 MBq,肿瘤平均吸收剂量为42.7 ± 34.0 Gy,健康肝为10.2 ± 3.7 Gy,全肝为7.9 ± 3.7 Gy,肺为1.5 ± 1.2 Gy。

要点

  • 188Re-SSS Lipiodol注射后摄取仅见于肝脏和肺部,且72小时内稳定。
  • 肿瘤平均吸收剂量42.7 ± 34.0 Gy,健康肝10.2 ± 3.7 Gy,全肝7.9 ± 3.7 Gy,肺1.5 ± 1.2 Gy。
  • 2个月CT显示4例患者疾病稳定,1例快速进展死亡被独立评估委员会视为治疗相关毒性。

核心结论

  • 188Re-SSS Lipiodol在放疗栓塞中具有有利的生物分布特征,是目前报道的放射性碘油化合物中体内稳定性最高的。
  • 这些初步结果需在完成I期Lip-Re 1试验后进一步确认。

研究设计与样本

  • I期Lip-Re 1临床试验的初步结果报告,纳入前6例肝细胞癌患者。
  • 基于注射后1、6、24、48和72小时的平面闪烁显像和SPECT分析生物分布,并量化血液、尿液和粪便样本。
  • 计算肿瘤与非肿瘤摄取比(T/NT),采用MIRD形式评估靶器官和肿瘤的吸收剂量。

主要发现

  • 188Re-SSS Lipiodol平均注射活度为1645 ± 361 MBq。
  • 摄取仅见于肝脏(肿瘤和健康肝)和肺部,且所有摄取随时间稳定。
  • 6小时血清中检测到平均1.4 ± 0.7%的给药活度,随后快速下降。
  • 72小时内平均1.5 ± 1.6%的给药活度经尿液和粪便排出。
  • SPECT检测到的活度中,90.7 ± 1.6%位于肝脏(肿瘤74.9 ± 1.8%,健康肝19.1 ± 1.7%),9.3 ± 1.6%位于肺部(右肺5.7 ± 1.1%,左肺3.7 ± 0.5%)。

关键数值与推荐

  • 平均吸收剂量:全肝7.9 ± 3.7 Gy,肿瘤42.7 ± 34.0 Gy,健康肝10.2 ± 3.7 Gy,肺1.5 ± 1.2 Gy。
  • 2个月CT显示4例患者疾病稳定。
  • 首例快速进展疾病患者在1个月死亡,最可能死于大规模肿瘤进展,但独立评估委员会保守地将其视为治疗相关毒性。

临床怎么用

  • 188Re-SSS Lipiodol经肝动脉注射后主要滞留于肝脏和肺部,全身泄漏低,可用于肝细胞癌的放疗栓塞。
  • 肿瘤吸收剂量远高于健康肝,但个体差异较大,需进一步验证剂量-疗效关系。

局限性

  • 仅为前6例患者的初步结果,样本量小。
  • 需完成I期Lip-Re 1试验以进一步确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of 188Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study. METHODS: Results of the first six patients included are reported. Analysis of the 188Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Quantification in blood, urine, and stool samples was performed. Determination of the tumour to non-tumour uptake ratio (T/NT) was calculated. Absorbed doses to target organs and tumours were evaluated using the MIRD formalism. RESULTS: The mean injected activity of 188Re-SSS Lipiodol was 1645 ± 361 MBq. Uptakes were seen in the liver (tumour and healthy liver) and the lungs only. All these uptakes were stable over time. A mean 1.4 ± 0.7% of 188Re-SSS Lipiodol administered was detected in serum samples at 6 h, declining rapidly thereafter. On average, 1.5 ± 1.6% of administered activity was eliminated in urine and feces over 72 h. Overall, 90.7 ± 1.6% of detected activity on SPECT studies was found in the liver (74.9 ± 1.8% in tumours and 19.1 ± 1.7% in the healthy liver) and 9.3 ± 1.6% in the lungs (5.7 ± 1.1% in right and 3.7 ± 0.5% in left lungs). Mean doses absorbed were 7.9 ± 3.7Gy to the whole liver, 42.7 ± 34.0Gy to the tumours, 10.2 ± 3.7Gy to the healthy liver, and 1.5 ± 1.2Gy to the lungs. Four patients had stable disease on CT scans at 2 months. The first patient with rapidly progressive disease died at 1 month, most probably of massive tumour progression. Due to this early death and using a conservative approach, the trial independent evaluation committee decided to consider this event as a treatment-related toxicity. CONCLUSION: 188Re-SSS Lipiodol has a favorable biodistribution profile concerning radioembolization, with the highest in-vivo stability among all radiolabeled Lipiodol compounds reported to date. These preliminary results must be further confirmed while completing this Phase I Lip Re1 study.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Delaunay K, Edeline J, Rolland Y, et al. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging. 2019. PMID: 30715571. doi:10.1007/s00259-019-04277-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。